Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Articles in this Series –
- Details on Approved Cancer Targeting Antibodies. (46 Molecules)
- Monoclonal Antibodies in Active Clinical Development – Developers, Pipeline, Target & Cancer Indication. (112 Molecules)
- Monoclonal Antibodies in Active Preclinical Development – Developers, Pipeline, Target & Cancer Indication. (200 Molecules)
- Details on Approved Cancer Targeting BiSpecific Antibodies. (XX Molecules)
- Bispecific Antibodies in Active Clinical Development – Developers, Pipeline, Targets & Cancer Indication. (XX Molecules)
- Bispecific Antibodies in Active Preclinical Development – Developers, Pipeline, Targets & Cancer Indication. (XX Molecules)
- Details on Approved Cancer Targeting Antibodies Drug Conjugates. (XX Molecules)
- Antibody Drug Conjugates in Active Clinical Development – Developers, Pipeline, Targets & Cancer Indication. (XX Molecules)
- Antibody Drug Conjugates in Active Preclinical Development – Developers, Pipeline, Targets & Cancer Indication. (XX Molecules)
Cancer Targeting Antibodies in Development
Antibody Drug Conjugates
Antibody Drug Conjugates (ADCs) are therapeutic entities with monoclonal antibody (mAb) backbone linked to cytotoxic drugs and are designed to improve/increase the therapeutic window of selected mAbs. ADCs now emerges as one of the hotspots for the research and development of anticancer drugs. Recent technology advances on new generation...
Read more
Discussion about this post